Apimeds Pharmaceuticals Us, INC. (APUS) — 8-K Filings

8-K Filings (8)

• 8-K Filing — Mar 26, 2026
• Apimeds Amends Bylaws, Reports Officer Changes on March 20, 2026 — Mar 25, 2026
  Apimeds Pharmaceuticals US, Inc. filed an 8-K on March 25, 2026, reporting significant corporate governance changes effective March 20, 2026. The filing include
• Apimeds Pharmaceuticals Files 8-K with Multiple Material Events — Dec 2, 2025 Risk: medium
  Apimeds Pharmaceuticals US, Inc. filed an 8-K on December 2, 2025, reporting several material events as of December 1, 2025. These include entering into a mater
• 8-K Filing — Nov 18, 2025
• Apimeds Pharmaceuticals Files 8-K for Bylaws and Financials — Oct 16, 2025 Risk: low
  Apimeds Pharmaceuticals US, Inc. filed an 8-K on October 16, 2025, reporting amendments to its Articles of Incorporation or Bylaws and financial statements. The
• Apimeds Pharmaceuticals Files 8-K — Jul 16, 2025 Risk: low
  Apimeds Pharmaceuticals US, Inc. filed an 8-K on July 16, 2025, reporting events as of July 15, 2025. The filing is a current report pursuant to Section 13 or 1
• Apimeds Pharmaceuticals Reports Officer and Director Changes — Jun 5, 2025 Risk: medium
  Apimeds Pharmaceuticals US, Inc. filed an 8-K on June 5, 2025, reporting changes effective May 30, 2025. The filing indicates a departure of directors or certai
• Apimeds Pharmaceuticals Files 8-K on Agreements and Equity Sales — May 12, 2025 Risk: medium
  On May 8, 2025, Apimeds Pharmaceuticals US, Inc. filed an 8-K report detailing several key events. These include entering into a material definitive agreement,

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX